Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dendreon will have to wait until mid-2009 at the earliest for final study results of its prostate cancer vaccine Provenge, after it failed to meet the primary endpoint in an interim look at the data